An Analytical Method for Assessing Stage-Specific Drug Activity in Plasmodium vivax Malaria: Implications for Ex Vivo Drug Susceptibility Testing

PLoS Neglected Tropical Diseases

Volumn 6, Issue 8, 2012, Pages

  Kerlin, Douglas H ^a   Boyce, Kane ^a   Marfurt, Jutta ^b   Simpson, Julie A ^c   Kenangalem, Enny ^d,e,f   Cheng, Qin ^g   Price, Ric N ^b,h   Gatton, Michelle L ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d Papuan Health and Community Development Foundation (PHCDF)   (Indonesia)

^e NATIONAL INSTITUTE OF HEALTH RESEARCH AND DEVELOPMENT   (Indonesia)

^f District Ministry of Health   (Indonesia)

^g AUSTRALIAN ARMY MALARIA INSTITUTE   (Australia)

^h UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ANTIMALARIAL AGENT; BENFLUMETOL; CHLOROQUINE; MEFLOQUINE; PIPERAQUINE; PYRONARIDINE;

ANTIMALARIAL ACTIVITY; ANTIMALARIAL DRUG SUSCEPTIBILITY; ARTICLE; ASSAY; CONTROLLED STUDY; DRUG RESPONSE; HUMAN; MAJOR CLINICAL STUDY; MODEL; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; PROTIST LIFE CYCLE STAGE; RETROSPECTIVE STUDY; SCHIZONT MATURATION TEST;

ADULT; ANTIMALARIALS; ASIA, SOUTHEASTERN; CHILD; CHILD, PRESCHOOL; CHLOROQUINE; HUMANS; MALARIA, VIVAX; PARASITIC SENSITIVITY TESTS; PLASMODIUM VIVAX; TIME FACTORS;

EID: 84865957899     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001772     Document Type: Article

References (21)

1. Price RN, Douglas NM, Anstey NM, (2009) New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance. Current Opinion in Infectious Diseases 22: 430-435 410.1097/QCO.1090b1013e32832f32814c32831.
2. Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, et al. (2007) Vivax malaria: Neglected and not benign. American Journal of Tropical Medicine and Hygiene 77: 79-87.
3. Tjitra E, Anstey NM, Sugiarto P, Warikar N, Kenangalem E, et al. (2008) Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: A prospective study in Papua, Indonesia. Plos Medicine 5: 890-899.
4. Galinski MR, Barnwell JW, (2008) Plasmodium vivax: who cares? Malaria Journal 7 (Supp 1): S9.
5. Mendis K, Sina BJ, Marchesini P, Carter R, (2001) The neglected burden of Plasmodium vivax malaria. American Journal of Tropical Medicine and Hygiene 64: 97-106.
6. Mueller I, Galinski MR, Baird JK, Carlton JM, Kochar DK, et al. (2009) Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. Lancet Infectious Diseases 9: 555-566.
7. Baird JK, (2009) Resistance to Therapies for Infection by Plasmodium vivax. Clinical Microbiology Reviews 22: 508-534.
8. Douglas NM, Anstey NM, Angus BJ, Nosten F, Price RN, (2010) Artemisinin combination therapy for vivax malaria. The Lancet Infectious Diseases 10: 405-416.
9. Kosaisavee V, Suwanarusk R, Nosten F, Kyle DE, Barrends M, et al. (2006) Plasmodium vivax: Isotopic, PicoGreen, and microscopic assays for measuring chloroquine sensitivity in fresh and cryopreserved isolates. Experimental Parasitology 114: 34-39.
10. Marfurt J, Chalfein F, Prayoga P, Wabiser F, Kenangalem E, et al. (2011) Ex Vivo Activity of Histone Deacetylase Inhibitors against Multidrug-Resistant Clinical Isolates of Plasmodium falciparum and P-vivax. Antimicrobial Agents and Chemotherapy 55: 961-966.
11. Muhamad P, Ruengweerayut R, Chacharoenkul W, Rungsihirunrat K, Na-Bangchang K, (2011) Monitoring of clinical efficacy and in vitro sensitivity of Plasmodium vivax to chloroquine in area along Thai Myanmar border during 2009-2010. Malaria Journal 10.
12. Russell BM, Udomsangpetch R, Rieckmann KH, Kotecka BM, Coleman RE, et al. (2003) Simple In Vitro Assay for Determining the Sensitivity of Plasmodium vivax Isolates from Fresh Human Blood to Antimalarials in Areas where P. vivax Is Endemic. Antimicrob Agents Chemother 47: 170-173.
13. Rieckmann KH, Campbell GH, Sax LJ, Ema JE, (1978) Drug sensitivity of Plasmodium falciparum: An in-vitro microtechnique. The Lancet 311: 22-23.
14. Rieckmann KH, Yeo AET, Edstein MD, (1996) Activity of PS-15 and its metabolite, WR99210, against Plasmodium falciparum in an in vivo in vitro model. Transactions of the Royal Society of Tropical Medicine and Hygiene 90: 568-571.
15. Russell B, Chalfein F, Prasetyorini B, Kenangalem E, Piera K, et al. (2008) Determinants of in vitro drug susceptibility testing of Plasmodium vivax. Antimicrobial Agents and Chemotherapy 52: 1040-1045.
16. Sharrock WW, Suwanarusk R, Lek-Uthai U, Edstein MD, Kosaisavee V, et al. (2008) Plasmodium vivax trophozoites insensitive to chloroquine. Malaria Journal 7: 94.
17. Siswantoro H, Russell B, Ratcliff A, Prasetyorini B, Chalfein F, et al. (2011) In Vivo and In Vitro Efficacy of Chloroquine against Plasmodium malariae and P. ovale in Papua, Indonesia. Antimicrobial Agents and Chemotherapy 55: 197-202.
18. World Health Organization (2001) In vitro micro-test (Mark III) for the assessment of the response of Plasmodium falciparum to chloroquine, mefloquine, quinine, amodiaquine, sulfadoxine/pyrimethamine and artemisinin. Division of Control of Tropical Diseases, World Health Organization.
19. R Development Core Team (2011) R: A language and environment for statistical computing. Vienna, Austria.
20. Lambros C, Vanderberg JP, (1979) Synchronization of Plasmodium falciparum erythrocytic stages in culture. Journal of Parasitology 65: 418-420.
21. Trang DTX, Huy NT, Kariu T, Tajima K, Kamei K, (2004) One-step concentration of malarial parasite-infected red blood cells and removal of contaminating white blood cells. Malaria Journal 3: 7.